BRD2 and childhood malignant neoplasm: Van Casteren et al. evaluated 248 long-term survivors of childhood cancer and they observed a significantly decreased inhibin B levels and increased FSH levels in men treated for Hodgkin and non-Hodgkin lymphoma, acute-myeloid leukemia, neuroblastoma, and sarcoma as compared to other malignancies.